Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu INRA

Home page

Micalis

FATTY ACIDS - Team leader: Alexandra D. GRUSS

Sandy-4

DREX (HDR)

+33 1 3465 2168

mail : Sandy GRUSS

Research project:

Bacterial incorporation of exogenous fatty acids and impact on fitness and virulence

I. Bacterial dialog with the environment relies on membrane fatty acids

Membranes are gatekeepers of all living cells. Phospholipids comprise about 40 percent of the membrane; the fatty acids comprising phospholipids determine many of their properties, including membrane fluidity and thickness. These intrinsic properties, plus the indirect consequences of phospholipids on other constituents such as lipid-anchored proteins or sugars, modulate bacterial integrity and the dialogue between bacteria and their environment.

II. Bacterial membranes are flexible and fatty acid replacement is common

The central role of membranes and their fatty acids in bacterial survival has thus spurred development of fatty acid synthesis (FASII) inhibitors as candidate antibacterial targets. It therefore came as a surprise that bacteria can basically sidestep anti-FASII molecules by using environmental fatty acids (eFAs) to replace endogenous fatty acids. Our team, in collaboration with the Poyart (Cochin Hospital) and Trieu-Cuot (Pasteur Institute) labs, uncovered this capacity in the Gram-positive pathogen Streptococcus agalactiae, by showing that a strain deleted for FASII remained infective (Nature, 2009). This is explained, as bacteria are exposed to fatty acids in the host that can be used as replacement when endogenous synthesis is blocked.

III. The case of Staphylococcus aureus

Our lab now focuses on the opportunist pathogen Staphylococcus aureus, a cause of farm animal disease and life-threatening human infections. Anti-FASII drugs have been promoted as a promising venue to fight S. aureus infection, and their development gained support based on claims that fatty acids specific to S. aureus are absolutely required, and cannot be recuperated from the host during infection. Our initial findings proved that FASII can be bypassed by high frequency point mutations that favor the use of eFAs (Nature Communications, 2016). Since then, we identified conditions in which wild type S. aureus overcomes FASII inhibitors without mutations in FASII within a few hours. Full fatty acid replacement upon growth with an anti-FASII occurs after a 6 to 10 hour latency phase. Our current studies of eFA replacement address the following question:

     1- Kinetics of eFA incorporation in both phospholipid positions: what, if any specificity of the S. aureus enzymes?

     2- What factors define the duration of latency before outgrowth of anti-FASII-refractive S. aureus that use eFA to compensate a FASII block?

     3- Can we design a combinatorial strategy that potentiates the action of anti-FASII when combined with other drugs?

ligne

Bibliography (2015-2018) :

Boudjemaa R, Cabriel C, Dubois-Brissonnet F, Bourg N, Dupuis G, Gruss A, Leveque-Fort S, Briandet R, Fontaine-Aupart MP and Steenkeste K. (2018) Failure of daptomycin to kill Staphylococcus aureus: impact of bacterial membrane fatty acid composition. Antimicrob Agents Chemother. 62(7). pii: e00023-18. doi: 10.1128/AAC.00023-18.

Morvan C, Halpern D, Kenanian G, Pathania A, Anba-Mondoloni J, Lamberet G, Gruss A and Gloux K (2017) The FASII bypass escape route from FASII inhibitors. Biochimie. DOI: 10.1016/j.biochi.2017.07.004.

Gloux K, Guillemet M, Soler C, Morvan C, Halpern D, Pourcel C, Thien HV, Lamberet G and Gruss A (2017). Clinical relevance of FASII bypass in Staphylococcus aureus. Antimicrob. Agents Chemother.  DOI:10.1128/AAC.02515-16.

Joubert L, Dagieu JB, Fernandez A, Derré-Bobillot A, Borezée-Durant E, Fleurot I, Gruss A, Lechardeur D. Visualization of the role of host heme on the virulence of the heme auxotroph Streptococcus agalactiae. Sci Rep. 2017 Jan 16

Morvan C, Halpern D, Kenanian, G, Hays C, Anba-Mondoloni J, Brinster S, Kennedy S, Trieu-Cuot P, Poyart C, Lamberet G, Gloux K, and Gruss A (2016). Environmental Fatty Acids Enable Emergence of Infectious Staphylococcus aureus Resistant to FASII-Targeted Antimicrobials. Nat Comm. DOI: 10.1038/ncomms12944.

Halpern D,  Gruss A (2015). A sensitive bacterial-growth-based test reveals how intestinal Bacteroides meet their porphyrin requirement. BMC microbiology, 15(1), 1.

__________

ORCID

__________

ligne

Collaborations:

ligne

Team members:

Jamila ANBA-MONDOLONI

Read more

Karine GLOUX

Read more

David HALPERN

Read more